JAK2/FLT3-IN-1
规格
| Cas Number | 2387765-27-5 |
| 规格或纯度 |
| 包装 | 10mg 或 5mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 20.83 mg/mL (44.55 mM; ultrasonic and warming and heat to 60°C) |
| 过滤标签 | 表观遗传学,JAK,FLT3,JAK/STAT Signaling,Protein Tyrosine Kinase/RTK,Stem Cell/Wnt |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | JAK2/FLT3-IN-1 是一种强效的口服活性 JAK2/FLT3 双抑制剂，对 JAK2、FLT3、JAK1 和 JAK3 的 IC 50 值分别为 0.7 nM、4 nM、26 nM 和 39 nM。JAK2/FLT3-IN-1 具有抗癌活性。 |
| 英文描述 |
JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. JAK2/FLT3-IN-1 has anti-cancer activity In Vitro JAK2/FLT3-IN-1 (0.008-1 μM; for 2 hours) down-regulates p-FLT3 in a dose-dependent manner. JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) has a dose-dependent effect on the induction of apoptosis in the MV4-11 cells. JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) strongly induces cell cycle arrest with a G1/G0 percentage of 85% at 100 nM in the MV4-11 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MV4-11 and SET-2 cells Concentration: 0.008, 0.04, 0.2, 1 μM Incubation Time: For 2 hours Result: Down-regulated p-FLT3 in a dose-dependent manner from 0.008 to 1 μM. Apoptosis AnalysisCell Line: MV4-11 cells Concentration: 5, 10, 50, 100 nM Incubation Time: For 2 hours Result: Had a dose-dependent effect on the induction of apoptosis in the MV4-11 cells. Cell Cycle AnalysisCell Line: MV4-11 cells Concentration: 5, 10, 50, 100 nM Incubation Time: For 2 hours Result: Induced cell cycle arrest with a G1/G0 percentage of 85% at 100 nM. In Vivo JAK2/FLT3-IN-1 (30 and 60 mg/kg/day; p.o.; for 14 days) exhibits significant antitumor effects . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NOD/SCID mouse models Dosage: 30 and 60 mg/kg Administration: Oral administration; daily; for 14 days Result: Exhibited significant antitumor effects. The tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model. Form:Solid IC50& Target:JAK2 0.7 nM (IC 50 ) FLT3 4 nM (IC 50 ) JAK1 26 nM (IC 50 ) JAK3 39 nM (IC 50 ) |